Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 92 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pegylated interferon alfa-2a (PEG) Clear all
Completed Phase 2 Interventional Results available

A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment

NCT00980330
View directory record Official record
Conditions
Hepatitis C
Interventions
TMC435, Placebo, Peg-IFN-alfa-2a (P), Ribavirin (R)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years to 70 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 4 Interventional Results available

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

NCT00087568
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
25
States / cities
Bakersfield, California • Pasadena, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

NCT00420784
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Matching Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 2 Interventional

A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C

NCT01482390
View directory record Official record
Conditions
Hepatitis C
Interventions
Ribavirin, Mericitabine, Peginterferon Alfa-2a, Placebo, Telaprevir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Birmingham, Alabama • Long Beach, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

NCT00627926
View directory record Official record
Conditions
Hepatitis C
Interventions
Pegylated Interferon Alfa 2a, Telaprevir, Ribavirin, Placebo
Biological · Drug · Other
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 3 Interventional

Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

NCT03719313
View directory record Official record
Conditions
Hepatitis Delta Virus
Interventions
Lonafarnib, Ritonavir, PEG IFN-alfa-2a, Placebo Lonafarnib, Placebo Ritonavir
Drug
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
18
States / cities
Fresno, California • Los Angeles, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 10, 2026, 1:02 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

NCT01459913
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Telaprevir, Pegylated Interferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 3 Interventional

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

NCT00411385
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
albumin interferon alfa-2b, peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Human Genome Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
933 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
28
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

NCT00535847
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated interferon alfa 2a
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3

NCT01808248
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF, PEG, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 2 Interventional

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

NCT01371578
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a, ribavirin tablet
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Dothan, Alabama • Montgomery, Alabama • Beverly Hills, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 4 Interventional Results available

A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C

NCT00394277
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
91
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

NCT01125189
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Daclatasvir, Placebo, peg-interferon alfa-2a, ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Montgomery, Alabama • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2015 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

NCT01625338
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SOF, RBV, Peg-IFN
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
67
States / cities
Birmingham, Alabama • Bakersfield, California • Colton, California + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Oct 10, 2026, 1:02 PM EDT
Not listed Phase 1Phase 2 Interventional

Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer

NCT00423397
View directory record Official record
Conditions
Non-melanomatous Skin Cancer
Interventions
PEG-interferon alfa-2a, gefitinib
Biological · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 3 Interventional

Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

NCT00040027
View directory record Official record
Conditions
Hepatitis C, Hepatitis C, Chronic
Interventions
thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a, placebo + PEGinterferon alfa-2a
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
46
States / cities
Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

NCT01389323
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Peg-Interferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
35
States / cities
Montgomery, Alabama • Long Beach, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 10, 2026, 1:02 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

NCT07623200
View directory record Official record
Conditions
Essential Thrombocythemia
Interventions
INCA033989, Best Available Treatment
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
43
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders

NCT01051921
View directory record Official record
Conditions
Hepatitis C
Interventions
CTS-1027, Pegylated interferon, Ribavirin
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
La Jolla, California • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

NCT00336479
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo
Drug · Other
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
36
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B

NCT01519960
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Years to 17 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2022 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

NCT01257204
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Placebo, Daclatasvir, Pegylated interferon alfa-2a, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Tulsa, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

NCT00758043
View directory record Official record
Conditions
Hepatitis C
Interventions
telaprevir, ribavirin, peginterferon alfa-2a
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 10, 2026, 1:02 PM EDT
Completed Not applicable Interventional

Directly Observed Hepatitis C Treatment in Methadone Clinics

NCT01442311
View directory record Official record
Conditions
Hepatitis C, Medication Adherence
Interventions
enhanced DOT (both pegylated interferon alfa-2a and ribavirin), standard DOT (PEG-DOT control arm)
Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 10, 2026, 1:02 PM EDT